Findings

What do systematic reviews say?

Refine by population, intervention, comparison or outcome
More filters
Evidence found and GRADE certainty

127 questions · 131 findings · 83 reviews

No studies found 27 · 20.6%GRADE not reported 15 · 11.5%Very low 46 · 35.1%Low 23 · 17.6%Moderate 16 · 12.2%High 4 · 3.1%

Summary of findings: high‐dose urate oxidase vs low‐dose urate oxidase

Frequency of adverse events ( · children with haematological malignancy at risk of tumour lysis syndrome

Summary of findings: high‐dose urate oxidase showed no clear difference in frequency of adverse events ( compared with low‐dose urate oxidase (low certainty).

1 finding from 1 review

Higher BP target (< 150‐160/95‐105 mmHg) vs lower BP target (< 140/90 mmHg)

Serious adverse events: cardiovascular events · older adults with primary hypertension

Higher BP target (< 150‐160/95‐105 mmHg) showed no clear difference in cardiovascular serious adverse events compared with lower BP target (< 140/90 mmHg) (low certainty).

1 finding from 1 review

High‐treatment‐dose vitamin D (greater than 1000 IU/day) vs low‐treatment‐dose vitamin D (400 IU/day to 1000 IU/day)

Withdrawals due to adverse events · people with inflammatory bowel disease

It is very uncertain whether high‐treatment‐dose vitamin D (greater than 1000 IU/day) changes withdrawals due to adverse events compared with low‐treatment‐dose vitamin D (400 IU/day to 1000 IU/day) (very low certainty).

1 finding from 1 review

Higher polyunsaturated fatty acid (PUFA) vs lower PUFA

Major adverse cardiac and cerebrovascular events · people with or without existing CVD, men and women

It is very uncertain whether higher polyunsaturated fatty acid (PUFA) changes major adverse cardiac and cerebrovascular events compared with lower PUFA (very low certainty).

1 finding from 1 review

Clobazam (low, medium and high doses) plus ASMs vs placebo plus ASMs

Number of participants with adverse events leading to study discontinuation · Lennox‐Gastaut syndrome, any age

Clobazam (low, medium and high doses) plus ASMs leads to higher number of participants with adverse events leading to study… compared with placebo plus ASMs (high certainty).

1 finding from 1 review

Summary of findings table ‐ Platinum‐resistant recurrent EOC: PARPi monotherapy vs chemotherapy alone

Adverse events (grade ≥ 3) · recurrent platinum‐resistant EOC

It is very uncertain whether summary of findings table ‐ Platinum‐resistant recurrent EOC: PARPi… changes any severe adverse events (grade 3 or higher) (G3+ SevAE) compared with chemotherapy (very low certainty).

1 finding from 1 review

Lay health worker‐ vs enhanced usual care

Adverse events ‐ death in past 12 months (RR > 1 denotes higher risk of death) · adult patients with alcohol dependence

It is very uncertain whether lay health worker‐led interventions changes adverse events ‐ death in past 12 months (RR > 1 denotes higher risk… compared with enhanced usual care (very low certainty).

1 finding from 1 review

Lidocaine vs disopyramide

Adverse events (AEs; adverse drug reaction): cardiac blocks (high‐degree atrioventricular block and bundle) · patients with myocardial infarction

It is very uncertain whether lidocaine changes adverse events (AEs; adverse drug reaction): cardiac blocks… compared with disopyramide (very low certainty).

1 finding from 1 review

Intervention not reported

Adverse events ‐ Ectopic pregnancy Melatonin lower dose versus melatonin higher dose№ of participants: 120(1 RCT) · women with subfertility
1 finding from 1 review